Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors()

PURPOSE: Advanced NSCLC harboring epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) typically progresses after initial response due to acquired resistance. TKIs are often continued beyond progressive disease by RECIST. We investigated the practice...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Nishino, Mizuki, Cardarella, Stephanie, Dahlberg, Suzanne E., Jackman, David M., Ramaiya, Nikhil H., Hatabu, Hiroto, Rabin, Michael S., Jänne, Pasi A., Johnson, Bruce E.
Format: Artigo
Langue:Inglês
Publié: 2012
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3580850/
https://ncbi.nlm.nih.gov/pubmed/23254265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2012.11.007
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires